tirzepatide ocular side effects Use of the dual GIP/GLP-1 drug (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort Ophthalmic complications observed in patients

Many patients who respond well to semaglutide treatment may benefit from the increased dose, particularly if they have not yet reached their weight management goals on lower doses

But we typically use transdermal

Tirzepatide was approved by the US Food and Drug Administration as Mounjaro for adults with type 2 diabetes to improve glycemic control on May 13, 2022, and as Zepbound for adults with obesity or those who are overweight who also have at least one weight-related medical problem on Nov 8, 2023

AHK-Cu is sold exclusively for in-vitro research and is not FDA-approved for therapeutic use in humans

Administering a 12 mg dose over 40 weeks resulted in an average weight loss of 16.8% for this population [2]